GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Myomo Inc (AMEX:MYO) » Definitions » ROE %

Myomo (MYO) ROE % : -98.34% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Myomo ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Myomo's annualized net income for the quarter that ended in Dec. 2023 was $-9.84 Mil. Myomo's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $10.01 Mil. Therefore, Myomo's annualized ROE % for the quarter that ended in Dec. 2023 was -98.34%.

The historical rank and industry rank for Myomo's ROE % or its related term are showing as below:

MYO' s ROE % Range Over the Past 10 Years
Min: -259.68   Med: -107.76   Max: -76.9
Current: -90.88

During the past 8 years, Myomo's highest ROE % was -76.90%. The lowest was -259.68%. And the median was -107.76%.

MYO's ROE % is ranked worse than
86.21% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs MYO: -90.88

Myomo ROE % Historical Data

The historical data trend for Myomo's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myomo ROE % Chart

Myomo Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -259.68 -172.73 -76.90 -98.50 -106.18

Myomo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -122.25 -132.27 -43.96 -81.80 -98.34

Competitive Comparison of Myomo's ROE %

For the Medical Devices subindustry, Myomo's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myomo's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's ROE % distribution charts can be found below:

* The bar in red indicates where Myomo's ROE % falls into.



Myomo ROE % Calculation

Myomo's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-8.148/( (6.359+8.989)/ 2 )
=-8.148/7.674
=-106.18 %

Myomo's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-9.84/( (11.023+8.989)/ 2 )
=-9.84/10.006
=-98.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Myomo  (AMEX:MYO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-9.84/10.006
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-9.84 / 19.024)*(19.024 / 15.818)*(15.818 / 10.006)
=Net Margin %*Asset Turnover*Equity Multiplier
=-51.72 %*1.2027*1.5809
=ROA %*Equity Multiplier
=-62.2 %*1.5809
=-98.34 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-9.84/10.006
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-9.84 / -9.556) * (-9.556 / -9.732) * (-9.732 / 19.024) * (19.024 / 15.818) * (15.818 / 10.006)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0297 * 0.9819 * -51.16 % * 1.2027 * 1.5809
=-98.34 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Myomo ROE % Related Terms

Thank you for viewing the detailed overview of Myomo's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myomo (MYO) Business Description

Traded in Other Exchanges
Address
137 Portland Street, 4th Floor, Boston, MA, USA, 02114
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Executives
Thomas F Kirk director
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Paul R Gudonis director, officer: Chief Executive Officer 9 HICKORY ROAD, MANCHESTER MA 01944
David A Henry officer: Chief Financial Officer
Harry Kovelman officer: Chief Medical Officer C/O MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Yitzchak Jacobovitz director MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Micah Mitchell officer: Chief Commercial Officer C/O MYOMO, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02139
Crowley Thomas Aloysius Jr. director 19 ST CLAIR AV, SPRING LAKE NJ 07762
Cliff Conneighton officer: Chief Marketing Officer 53 DEPOT ROAD, HOLLS NH 03049
Jonathan Naft officer: VP, General Manager C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Brandon M Green officer: Chief Medical Officer C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ralph A Goldwasser officer: Chief Financial Officer BNN CORP, 150 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Davie Mendelsohn officer: VP, Sales C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Steve Sanghi director 2355 W CHANDLER BLVD, CHANDLER AZ 85224-6199
Amy K. Knapp director 75 N. MOUNTAIN AVE, MONTCLAIR NJ 07042